Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. - Test2 - elhamkhani - TriplyDB

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33326148

about

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages Chemotherapy, radiotherapy, chemoradiotherapy and combination therapy in localised and locally advanced pancreatic cancer Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer Recent progress in pancreatic cancer Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids Pancreatic Cancer from Molecular Pathways to Treatment Opinion Pancreatic cancer from bench to bedside: molecular pathways and treatment options Viro-immune therapy: A new strategy for treatment of pancreatic cancer Chinese Herbal Medicines as an Adjunctive Therapy for Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis Advances in systemic therapy for advanced pancreatobiliary malignancies Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Systemic therapies for pancreatic cancer--the role of pharmacogenetics Pancreatic cancer treatment and research: an international expert panel discussion.Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Advances in chemotherapy for pancreatic cancer FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer Clinical Translation of Nanomedicine.Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative netw Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer.Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer Recent treatment advances and novel therapies in pancreas cancer: a review.Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer Personalising pancreas cancer treatment: When tissue is the issue.Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer.Current and future systemic treatment options in metastatic pancreatic cancer.Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).

P2860

Q21092323-2F33819A-C2CC-4F45-9773-DF57E686550F Q24194621-5766FA00-35D2-4319-AD0C-7FB3916570D9 Q24202423-24379687-C91C-44E1-8107-26DD651CA8F8 Q24626346-E7E05C4C-BBEA-4A78-B0A3-6CBE518B12DC Q26739062-187F978D-C0EC-413A-A5F6-EB697D6CD2C8 Q26743482-7288A57D-841D-42E6-B620-0106D07815EF Q26747524-389F413A-1286-468D-9388-E927EC35FFC7 Q26774641-0722DFAA-FDF2-4254-AC0E-83F39AA87FCF Q26774931-E58F6744-5876-480F-B812-96622D84E4FC Q26822703-9961B9A9-3ACE-4A27-9068-A9A347A63488 Q26830913-FDA85775-525A-481C-AA61-2A6B3E9000FB Q27021716-9B5CE459-31C6-4137-BA60-FBE757C6242F Q27690868-932429FD-335F-4BF0-AD9B-F01B5EBE0A40 Q28077772-6956978F-C627-4ED5-9AB7-9F67E693A6B6 Q28082919-C8E25433-A103-4C8E-A9FD-BC2C8B42B312 Q28085711-3772DDEF-3B63-4684-90E6-8E86EC6C5AE1 Q28483623-5467DDEF-54D5-4C43-B736-B91742BD098C Q28534413-1C4BF942-0FE0-453E-8BBD-FE28347974E6 Q28543464-CA2A9C08-1EBD-4847-8696-50A0F2D45552 Q30355939-752FE090-0A7E-43AA-A87D-6DB64AF23EB2 Q33387945-E00A4967-DC55-4CC9-84E4-56406ED0B7C8 Q33396393-A1382537-2817-4DEE-951A-8F67A366BD95 Q33401811-15E331DD-FA49-41E6-9C3F-925BBC3A8A1D Q33403498-5FA0839C-3C9A-4828-9118-9C1725ADCC71 Q33406415-B995B498-7742-4BF8-823D-741D504E244A Q33415922-64004FD4-5401-4432-8530-722F462A557C Q33423308-EB67B9DD-22F5-42CD-8641-078AEEC76F6C Q33427177-2B85DE24-C522-4C0D-8EB0-84F79CFBFC93 Q33428016-4205C824-229E-4DE5-AB1C-22BDD07AE194 Q33439342-D971AA17-4870-428F-8067-87DE9BCB1320 Q33440500-F84F0AF8-D908-41E3-A92A-33E4C5EB5E36 Q33621256-4E0B2CEF-6B2A-4B62-B39E-4100AE6FA4CE Q33625168-7AF49513-5F51-4955-B5C3-1CFF04BADD82 Q33632330-F39388A8-DC35-44F3-B05F-E15D9CFFABF3 Q33728198-59AB3A1E-54EE-4EAE-AD6F-F8C32A69A5D4 Q33801384-73A19216-0481-4277-B3A7-C97B4F223A04 Q33898080-61EED5FA-CCAD-4118-AE27-3C5E0C1E92B7 Q33915812-1F910089-36B5-4169-9B3F-24F434D2CD25 Q33948033-6BF9455B-1158-4E6F-B376-3AD0C1A09757 Q33989437-8557EF5A-5333-4CB6-8BFF-C0D487CCF560

P2860

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33326148

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@ast

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@en

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@nl

type

label

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@ast

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@en

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@nl

prefLabel

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@ast

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@en

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@nl

P1433

Q33326148-EFA435C8-B1B7-48AF-AFCE-BA862DF7824B

P1476

Q33326148-2EEC9EA9-AD59-49FF-A52F-4FF47949DFA1

P2093

Q33326148-3B526325-8F16-4F68-95E9-4352E8C96FC4

Q33326148-4247088C-1AE2-4826-9E01-BE0F411C0083

Q33326148-8D06CD46-B490-4E3A-A15E-7D42A17419CC

Q33326148-CB8BF95F-F136-44EB-901D-8526DE81411B

P2860

Q33326148-04A15E97-EB59-4D8D-94A1-D8C70E065B28

Q33326148-09D73FBD-D0DF-409C-B38E-61972B12A2A7

Q33326148-1CB10596-513E-4E76-93F2-4C1BF8AAA98C

Q33326148-315A7E08-9D3E-4EB7-9201-981BEB8E120C

Q33326148-42EA4AE7-6058-4DA9-9961-29FEF2B1CC8E

Q33326148-439AA07E-FC3C-48F6-A5F5-C752E7A1130A

Q33326148-506C2BB8-076C-4706-8796-A4CE4B78176F

Q33326148-50D34530-2592-45AA-AFDA-824839421749

Q33326148-66FD13F1-695F-4A9B-81AB-224145784522

Q33326148-808AE050-5642-47C4-9244-D2FEB7419ACB

P2888

Q33326148-F9392106-E39E-40FA-94A1-AB29A8651F0E

P304

Q33326148-03DFAD8D-8E1A-4ACB-9A06-52F45C518A90

P31

Q33326148-67f568ce-c7ca-4f6f-8def-ec7fabde55fe

Q33326148-EDB3D53F-CBE4-4549-8AEA-2823D97A952E

P356

Q33326148-ECB8ACF7-47A9-4843-8A4A-7F67A632403F

P407

Q33326148-0377A699-E115-46A0-BE76-2097031597D5

P478

Q33326148-A3B9E6A3-1368-476D-B3E8-268F83603FDE

P50

Q33326148-851364ED-7C99-40E2-8390-869114CDCB69

P577

Q33326148-606B829E-4A9C-4778-A24E-F815B9BE9F5E

P5875

Q33326148-E2985BE8-13F3-410B-B765-AAA8B64E1884

P6179

Q33326148-E043E0C1-4062-43B2-BADF-89A97A31BA3B

P698

Q33326148-67863555-BB17-4BA2-84E7-6441062907C6

P921

Q33326148-2CA6117A-E66F-4B8F-9372-71EBA84844A4

Q33326148-37B3CE2F-B8F7-464B-BC53-5020BF8BC8BA

P932

Q33326148-079B329A-6AF8-45D7-B284-353915B44E4B

P356

P1433

P1476

Meta-analysis of randomized tr ...... in advanced pancreatic cancer.

@en

P2093

Axel Hinke

http://www.w3.org/2001/XMLSchema#string

Christophe Louvet

http://www.w3.org/2001/XMLSchema#string

Stefan Boeck

http://www.w3.org/2001/XMLSchema#string

Volker Heinemann

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.

P2888

P304

82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-8-82

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Labianca

P577

2008-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5478474

http://www.w3.org/2001/XMLSchema#string

P6179

1005285779

http://www.w3.org/2001/XMLSchema#string

P698

18373843

http://www.w3.org/2001/XMLSchema#string

P921

P932

2292732

http://www.w3.org/2001/XMLSchema#string